Skip to main content
IPHA
NASDAQ Life Sciences

Innate Pharma's IPH4502 Hits 33% ORR at MTD in Phase 1; Dose Optimization Slated for H1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.14
Mkt Cap
$148.14M
52W Low
$1.17
52W High
$2.71
52W Position info
2.6% below low
Off High info
58% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

IPHA is trading near its 52-week low of $1.17 (2.6% below the low) on elevated volume (2.6× avg).

Summary

Innate Pharma reported initial Phase 1 data for its Nectin-4 ADC IPH4502, showing a manageable safety profile with stomatitis as the only dose-limiting toxicity, a 33% ORR (2/6) at the 3.6 mg/kg MTD in non-urothelial tumors, and 3 partial responses among 19 post-enfortumab vedotin urothelial patients. Dose optimization is starting, with a first patient planned in H1 2027.


Key Events · Product Development and Regulatory · IPHA

  • IPH4502 Phase 1 Data Presented at ENA 2026

    The study enrolled 76 patients with advanced solid tumors across six dose levels from 0.6 to 3.6 mg/kg every three weeks; patients had a median of 3.5 prior lines of therapy and represented more than 10 tumor types.

  • 33% ORR at Maximum Tolerated Dose

    At the 3.6 mg/kg MTD, objective response rate was 33% (2/6) in non-urothelial tumors, with responses seen across low, moderate and high Nectin-4 expression levels.

  • Clean Safety: Stomatitis Only DLT

    Stomatitis was the only dose-limiting toxicity, and there was no febrile neutropenia, no hematologic DLTs and no peripheral neuropathy signal. Grade 3+ TEAEs hit 43.4% of patients, including Grade 3+ anemia in 11.8%; stomatitis occurred in 27.6% overall (3.9% Grade 3+).

  • Post-EV Urothelial Activity

    Among 19 urothelial cancer patients, all previously treated with enfortumab vedotin, there were 3 partial responses (1 confirmed, 2 unconfirmed) and an unconfirmed disease control rate of 68.4% [46.0-84.6].


Analysis · IPHA · Life Sciences

The first hard clinical readout on IPH4502 — the ADC now leading Innate's proprietary pipeline — puts tolerability front and center. Stomatitis was the only dose-limiting toxicity, with no febrile neutropenia, no hematologic DLTs and no peripheral neuropathy signal, a cleaner safety picture than MMAE-based ADCs typically show. Antitumor activity appeared across tumor types and Nectin-4 expression levels. In the hardest-to-treat group — 19 urothelial patients all previously on enfortumab vedotin — there were 3 partial responses and a 68.4% unconfirmed disease control rate. Against that, the response data are early and mostly unconfirmed, and the MTD cohort where the 33% ORR was seen had only 6 patients. Dose optimization in post-EV urothelial cancer is now getting under way, with the first patient planned for H1 2027, so a recommended Phase 2 dose remains more than a year out. For a company that reported negative equity of €40.5M at H1 2026, this asset is the equity story, and the data support continued development without an immediate safety setback.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IPHA was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $148.1M. The 52-week trading range was $1.17 to $2.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IPHA - Latest Insights

IPHA
Nov 05, 2026, 6:20 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.14 info
Change: -$0.320 (-22%) info
Market Cap: $148.14M info
IPHA
Oct 27, 2026, 7:13 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.14 info
Change: -$0.320 (-22%) info
Market Cap: $148.14M info
IPHA
Sep 17, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $1.14 info
Change: -$0.7936 (-41%) info
Market Cap: $148.14M info
IPHA
Aug 19, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.14 info
Change: -$0.980 (-46%) info
Market Cap: $148.14M info
IPHA
Aug 10, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.22
Real-time Price: $1.14 info
Change: -$1.08 (-49%) info
Market Cap: $148.14M info